Below are the most recent publications written about "Drugs, Generic" by people in Profiles.
-
Lee JK, Lee HN, Agrawal S, Balsamo JA, Clerman A, Denies S, De Groot A, Fry J, Gaudenzio N, Graves AJ, Howard KE, Hwang S, Jawa V, Jin Y, Kelly-Baker L, Knowlton E, Kolenc F, Sivakumar KK, Lee JH, Li Y, Liang L, Liu D, Liu Y, Lionberger R, Luke MC, Manangeeswaran M, Mendoza M, Murphy I, Norcross M, Polli JE, Puig M, Rao Sp N, Rogers H, Schwendeman A, Siegel R, Shubow S, Smith N, Thacker SG, Tourdot S, Yang K, Zhang L, Zhang D, Smith CJ, Pang ES, Verthelyi D. Proceedings of the 2024 FDA-CRCG Workshop: Scientific and Regulatory Considerations for Assessment of Immunogenicity Risk for Generic Peptide and Oligonucleotide Drug Products. AAPS J. 2026 Feb 12; 28(2):61.
-
Hong M, Shcherbakova N. Comparison of Discounted and Undiscounted Cash Prices for Cardiovascular Medications by Type of US Community Pharmacy. J Gen Intern Med. 2021 01; 36(1):114-120.
-
Mo Y, Shcherbakova N, Zeibeq J, Muzykovsky K, Li WK, Gasperino J. Clinical and economic impact of the use of dexmedetomidine for sedation in the intensive care unit compared to propofol. Int J Clin Pharm. 2020 Dec; 42(6):1419-1424.
-
Gor D, Lee TA, Schumock GT, Walton SM, Gerber BS, Nutescu EA, Touchette DR. Adherence and Persistence with DPP-4 Inhibitors Versus Pioglitazone in Type 2 Diabetes Patients with Chronic Kidney Disease: A Retrospective Claims Database Analysis. J Manag Care Spec Pharm. 2020 Jan; 26(1):67-75.
-
Bertoldi AD, Chaves LA, Ross-Degnan D, Luiza VL, Emmerick ICM, Silva RMD, Campos MR. Brazilian generics market change after Farm?cia Popular program. Rev Saude Publica. 2019; 53:94.
-
Singh S. The Safety of Generic Prescription Drugs in the United States. Drug Saf. 2018 Apr; 41(4):325-328.
-
Iyer G, Marimuthu SP, Segal JB, Singh S. An Algorithm to Identify Generic Drugs in the FDA Adverse Event Reporting System. Drug Saf. 2017 09; 40(9):799-808.
-
Marimuthu SP, Iyer G, Segal JB, Singh S. Patient-relevant outcomes associated with generic tamsulosin, levothyroxine and amphetamine in the FDA Adverse Event Reporting System: a pilot study. J Comp Eff Res. 2017 Jul; 6(5):437-447.
-
Albrecht J, Lebwohl M, Asgari MM, Bennett DD, Cook A, Evans CC, Green LJ, Hodge JA, Kourosh AS, Maloney ME, Howard LM, Olsen EA, Rosenberg SP, Rubin A, Stough DB, Taylor SC, Brod BA. The state and consequences of dermatology drug prices in the United States. J Am Acad Dermatol. 2016 Sep; 75(3):603-605.
-
Sacks NC, Burgess JF, Cabral HJ, Pizer SD. Myopic and Forward Looking Behavior in Branded Oral Anti-Diabetic Medication Consumption: An Example from Medicare Part D. Health Econ. 2017 06; 26(6):753-764.